Table 2.
Association of tumor characteristics with prolactin receptor expression among 736 women with breast cancer (pre- and post-menopausal) from the Polish Breast Cancer Study
| PRLR staining (negative or low) N (%) | PRLR staining (strong) N (%) | p Value* | |
|---|---|---|---|
| Menopausal status N = 736 | |||
| Pre-menopausal | 29 (20.4) | 113 (79.6) | |
| Post-menopausal | 98 (16.5) | 496 (83.5) | 0.27 |
| PRL serum levels** N = 349 | |||
| Low | 30 (17.9) | 138 (82.1) | |
| High | 30 (16.9) | 148 (83.2) | 0.81 |
| Histological type N = 713 | |||
| Ductal | 106 (17.6) | 488 (82.2) | |
| Lobular | 17 (14.3) | 102 (85.7) | 0.35 |
| Tumor size N = 715 | |||
| ≤2 cm | 42 (11.9) | 310 (88.1) | |
| >2 cm | 79 (21.8) | 284 (78.2) | 0.0005 |
| Tumor grade N = 595 | |||
| Well/moderately differentiated | 35 (10.8) | 288 (89.2) | |
| Poorly differentiated | 80 (29.4) | 192 (70.6) | 1.2x10-08 |
| Axillary node metastasis N = 716 | |||
| Node negative | 62 (15.7) | 333 (84.3) | |
| Node positive | 60 (18.7) | 261 (81.3) | 0.29 |
| ER N = 732 | |||
| Negative | 50 (20.1) | 199 (79.9) | |
| Positive | 76 (15.7) | 407 (84.3) | 0.14 |
| PR N = 731 | |||
| Negative | 70 (18.4) | 311 (81.6) | |
| Positive | 56 (16.0) | 294 (84.0) | 0.40 |
| HER2 N = 721 | |||
| Negative | 104 (16.3) | 534 (83.7) | |
| Positive | 20 (24.1) | 63 (75.9) | 0.08 |
| ER/PR N = 730 | |||
| ER+ PR+ | 49 (15.6) | 265 (84.4) | |
| ER+ PR− | 27 (16.1) | 141 (83.9) | |
| ER− PR+ | 7 (19.4) | 29 (80.6) | |
| ER− PR− | 43 (20.3) | 169 (79.7) | 0.15 |
| ER/PR/HER2 N = 721 | |||
| ER+ or PR+ and HER2− | 78 (15.5) | 425 (84.5) | |
| ER+ or PR+ and HER2+ | 5 (35.7) | 9 (64.3) | |
| ER− and PR− and HER2+ | 9 (17.3) | 43 (82.7) | |
| ER− and PR− and HER2− | 32 (21.1) | 120 (78.9) | 0.11 |
Not all strata sums to 100 % due to rounding
*p Values from χ 2 test
**Category for PRL levels assigned using median PRL levels for the subset of cases with this measurement